Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | PI4KA | P42356 | 2/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367441 | 0.74 | PI4KA (0.50) | ALDH1A1CYP3A4CYP3A5BRD4PI4KA | |
| SCHEMBL30788403 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP3A5BRD4PI4KA | |
| SCHEMBL29804946 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP3A5BRD4PI4KA | |
| SCHEMBL7108989 | 0.74 | PI4KA (0.50) | ALDH1A1CYP3A4CYP3A5BRD4PI4KA | |
| SCHEMBL1165562 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP3A5BRD4PI4KA | |
| SCHEMBL2493987 | 0.74 | BRD4 (0.51) | ALDH1A1BRD4PI4KAPI4K2BPI4K2A | |
| SCHEMBL19778900 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP3A5BRD4PI4KA | |
| SCHEMBL323982 | 0.74 | ALDH1A1 (0.52) | ALDH1A1CYP3A4CYP3A5BRD4PI4KA | |
| SCHEMBL22830483 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP3A5BRD4PI4KA | |
| SCHEMBL3974202 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP3A5BRD4PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3444238-B1 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | SATO PHARMA (JP) | 2021-12-08 | — | — | EP | disclosed |
| EP-3444238-A2 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | Sato Pharmaceutical Co., Ltd. (JP) | 2019-02-20 | — | — | EP | disclosed |
| EP-2878594-B1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMA (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-9650380-B2 | Difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20170044158-A1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-9512119-B2 | Difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150191463-A1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-09 | — | — | US | disclosed |
| EP-2878594-A1 | DIFLUOROMETHYLENE COMPOUND | Sato Pharmaceutical Co., Ltd. (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044158-A1 | DIFLUOROMETHYLENE COMPOUND | XDH, URB2, MNAT1 | ALDH1A1 271/4885CYP3A4 1238/4885CYP3A5 2240/4885 |
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | ALDH1A1 2782/4885CYP3A4 1756/4885CYP3A5 1051/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ALDH1A1 1717/4885CYP3A4 525/4885CYP3A5 439/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ALDH1A1 1717/4885CYP3A4 525/4885CYP3A5 439/4885 |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | ALDH1A1 1934/4885CYP3A4 2048/4885CYP3A5 2151/4885 |
| US-20150191463-A1 | DIFLUOROMETHYLENE COMPOUND | XDH, SULT1A1, RFT1 | ALDH1A1 243/4885CYP3A4 1116/4885CYP3A5 1582/4885 |
| US-20150203490-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | ALDH1A1 487/4885CYP3A4 2623/4885CYP3A5 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.